Doximity Inc (DOCS) Shares Surge 4.5% -- What GF Score of 86 Tells Investors
On August 28, 2026, Doximity Inc (DOCS) shares rose 4.5% to a current price of $26.73. This performance occurred amidst a 52-week range of $17.15 to $76.51, ind
DOCS - Doximity, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$27.64
DETAILS
HIGH:
$41.00
LOW:
$18.00
MEDIAN:
$25.50
CONSENSUS:
$27.64
UPSIDE:
5.02%
Stock News
Doximity Inc (DOCS) Shares Surge 3.4% -- What GF Score of 82 Tells Investors
On August 27, 2026, Doximity Inc (DOCS) shares rose 3.4% to a current price of $25.59, reflecting a significant shift amidst a 52-week range of $17.15 to $76.51
Financial Contrast: Doximity (NYSE:DOCS) and MedPeer,Inc. (OTCMKTS:MDPEF)
MedPeer,Inc. (OTCMKTS:MDPEF - Get Free Report) and Doximity (NYSE: DOCS - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations. Earnings and Valuation This table compares MedPeer,Inc. and Doximity"s gross
Overworked Doctors Bet on AI to Boost Their Pay
[url="]Doximity[/url], Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are f
Overworked Doctors Bet on AI to Boost Their Pay
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected source of optimism in AI. Rather than viewing the technology as a threat, nearly a quarter expect it to increase their total compensation within the next year, and two-thirds believe staying current with AI will give them a meaningful earnings edge over peers who don't. The findings are part of Dox.
Reasons to Retain Doximity Stock in Your Portfolio for Now
DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.
A Doximity Director Moved 7,500 Shares the Day the Stock Popped 33%. Here's What to Know
This sale was executed under a pre-established Rule 10b5-1 trading plan adopted in February.
What Investors Should Know of This Doximity Officer's Latest Insider Transaction
The transaction involved the exercise of options and a subsequent disposition valued at $140,400 at $24.84 per share. The activity was split between a Rule 10b5-1 trading plan sale to cover tax obligations and mandated shares withheld by the issuer for restricted stock unit vesting.
Doximity Handed Its President 150,000 Options Last Month. Here's What the Latest Filing Signals for Investors
The shares traded represent about $111,154 in total value based on the execution price on August 15. This disposition reduced the insider's direct equity holdings by 8%.
Doximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know.
The disposition involved 15,311 shares valued at about $380,000 based on a weighted average price of $24.80 per share. The transaction reduced the insider's direct holdings by 3% following the underlying vesting event.
Doximity's Co-Founder Just Filed a Form 4. Is There Anything in It Worth Worrying About?
The CEO disposed of 8,505 shares for approximately $211,000 based on the transaction-date pricing. This transaction represented just 0.3% of the executive's direct equity holdings.
Truist Lifts Doximity Target to $24 and Stays on Hold
Doximity (DOCS), a digital platform for US medical professionals, rose 0.46% premarket after Truist Securities raised its price target to $24 from $19 and reite
Atlassian and Doximity Just Surged 30% After Earnings: 3 Software Stocks with the Same Setup
Recent commentary in the DevSecOps sector has been positive, which could help fuel GitLab's revenue. UiPath is a highly shorted stock that could defy expectations.
Here Are Monday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Apple, Dicks Sporting Goods, Domino’s Pizza, Doximity, NetApp, SanDisk, Trade Desk, and More
Apple just got slapped with an Underperform rating while Trade Desk faces a brutal price target, but some names on Monday's analyst radar are picking up surprise upgrades that could shift the conversation entirely.
Why Doximity Stock Skyrocketed on Friday
Doximity's AI assistant is earning favorable reviews from independent researchers. Customer usage of Doximity's AI services is soaring.
Doximity: I Called The Pop Over A Month Ago, But Now Is The Time To Wait (Rating Downgrade)
Doximity delivered strong fiscal Q1 2027 results, validating my prior bullish stance on valuation and AI-driven growth. The stock surged over 30% intraday, reflecting the market's recognition of DOCS's evolving business model and earnings strength. DOCS is transforming physician searches into a new commercial marketplace, leveraging AI Search to monetize real-time physician intent.
Doximity Q1 Earnings Call Highlights
Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.
DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up
Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.
Sell Doximity Into The Major Rally Following Its Q1 Results
Doximity, Inc. surged over 180% pre-market after its Q1 FY27 print, despite only marginally beating on revenue and missing on earnings. Fiscal Q3 revenue guidance of $170.5M at the midpoint is about 13% above consensus, signaling a potential inflection in growth expectations. Recent growth had slowed to just 5% in Q4, so the new guidance represents a notable acceleration relative to prior quarters.
Doximity stock is reversing post-earnings rally: why that shouldn't surprise you
Doximity (DOCS) stock as much as doubled on Friday morning after the digital platform for health care professionals posted a solid Q1 sales beat and issued seemingly impressive full-year guidance. Still, a closer look under the hood suggests these explosive gains are built on a fragile foundation, and the company might just end up paring them back in the days ahead.
Price Targets
Doximity Inc (DOCS) PT Raised to $24 at Truist Securities
$24.00
(was $24.99)
Jailendra Singh
·
Truist Financial
Doximity price target raised to $41 from $27 at Needham
$41.00
(was $30.19)
Scott Berg
·
Needham
Doximity price target raised to $40 from $22 at Evercore ISI
$40.00
(was $20.66)
Elizabeth Anderson
·
Evercore ISI
Doximity price target raised to $30 from $20 at BMO Capital
$30.00
(was $20.66)
BMO Capital
Doximity price target raised to $36 from $30 at Canaccord
$36.00
(was $20.66)
Canaccord Genuity
Doximity downgraded to Equal Weight from Overweight at Barclays
$20.00
(was $18.01)
Barclays
Doximity price target lowered to $19 from $29 at Truist
$19.00
(was $17.87)
Jailendra Singh
·
Truist Financial
Doximity price target lowered to $20 from $25 at BMO Capital
$20.00
(was $23.39)
Sean Dodge
·
BMO Capital
Doximity price target lowered to $27 from $55 at Needham
$27.00
(was $23.39)
Scott Berg
·
Needham
Doximity price target lowered to $26 from $34 at Mizuho
$26.00
(was $23.39)
Mizuho Securities
Doximity price target lowered to $30 from $34 at Canaccord
$30.00
(was $23.39)
Canaccord Genuity
Doximity price target lowered to $24 from $28 at Goldman Sachs
$24.00
(was $23.39)
Goldman Sachs
Doximity price target lowered to $35 from $49 at Morgan Stanley
$35.00
(was $23.39)
Craig Hettenbach
·
Morgan Stanley
Doximity price target lowered to $25 from $31 at Leerink
$25.00
(was $23.39)
Michael Cherny
·
Leerink Partners
Doximity downgraded to Equal Weight from Overweight at Wells Fargo
$18.00
(was $23.39)
Wells Fargo
Doximity downgraded to Hold from Buy at Jefferies
$19.00
(was $23.39)
Jefferies
Doximity downgraded to Neutral from Outperform at Baird
$18.00
(was $23.39)
Vikram Kesavabhotla
·
Robert W. Baird
Doximity price target lowered to $32 from $45 at Wells Fargo
$32.00
(was $25.98)
Wells Fargo
Doximity downgraded to Hold from Buy at Truist
$29.00
(was $24.71)
Truist Financial
Freedom Capital Markets Starts Doximity Inc (DOCS) at Buy
$31.00
(was $24.91)
Gene Mannheimer
·
Loop Capital Markets